Edgar Lomax Co. VA Decreases Position in Medtronic PLC $MDT

Edgar Lomax Co. VA decreased its holdings in Medtronic PLC (NYSE:MDT) by 22.6% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 260,930 shares of the medical technology company’s stock after selling 76,155 shares during the quarter. Medtronic comprises about 1.9% of Edgar Lomax Co. VA’s investment portfolio, making the stock its 19th largest holding. Edgar Lomax Co. VA’s holdings in Medtronic were worth $24,851,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Brighton Jones LLC increased its holdings in Medtronic by 1,368.0% during the 4th quarter. Brighton Jones LLC now owns 39,989 shares of the medical technology company’s stock worth $3,194,000 after purchasing an additional 37,265 shares during the period. Sivia Capital Partners LLC grew its position in shares of Medtronic by 9.6% during the second quarter. Sivia Capital Partners LLC now owns 4,356 shares of the medical technology company’s stock worth $380,000 after buying an additional 381 shares in the last quarter. NewSquare Capital LLC increased its stake in shares of Medtronic by 71.5% during the second quarter. NewSquare Capital LLC now owns 657 shares of the medical technology company’s stock worth $57,000 after buying an additional 274 shares during the period. Ellevest Inc. raised its holdings in Medtronic by 3.2% in the second quarter. Ellevest Inc. now owns 6,652 shares of the medical technology company’s stock valued at $580,000 after acquiring an additional 207 shares in the last quarter. Finally, Atlantic Union Bankshares Corp lifted its stake in Medtronic by 60.4% in the second quarter. Atlantic Union Bankshares Corp now owns 17,273 shares of the medical technology company’s stock worth $1,506,000 after acquiring an additional 6,504 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Medtronic

In other news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares in the company, valued at approximately $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 0.26% of the company’s stock.

Medtronic Stock Performance

NYSE MDT opened at $92.96 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The company has a market capitalization of $119.35 billion, a PE ratio of 25.89, a P/E/G ratio of 2.40 and a beta of 0.71. The company has a fifty day moving average of $98.80 and a two-hundred day moving average of $96.95.

Medtronic (NYSE:MDT) last posted its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The business had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, analysts expect that Medtronic PLC will post 5.46 earnings per share for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 17th. Shareholders of record on Friday, March 27th will be paid a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.1%. Medtronic’s payout ratio is currently 79.11%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Sunday, March 1st. Daiwa Securities Group lowered their target price on shares of Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. William Blair raised Medtronic from a “market perform” rating to an “outperform” rating in a report on Tuesday, January 6th. Sanford C. Bernstein lifted their price target on Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Finally, Royal Bank Of Canada upped their price objective on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

More Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Board approved a cash dividend of $0.71 for Q4 FY2026, reinforcing Medtronic’s long track record as a dividend grower and supporting income‑focused investor demand. Medtronic announces cash dividend for fourth quarter of fiscal year 2026
• Positive Sentiment: Medtronic launched the MiniMed Go Smart MDI system with the Simplera sensor in Europe, expanding its connected diabetes portfolio and addressing long‑term growth in continuous glucose monitoring and smart‑pen integration. Medtronic’s New MiniMed Go Highlights Digital Diabetes Push And Valuation Gap
• Positive Sentiment: Medtronic and GE HealthCare expanded their patient‑monitoring alliance, which could broaden distribution for products like Nellcor pulse oximetry and support recurring revenue streams. Medtronic, GE HealthCare expand patient monitoring alliance
• Positive Sentiment: Industry reports continue to rank Medtronic among leaders in biosensors and continuous glucose monitoring, supporting the company’s strategic position in a fast‑growing addressable market. Biosensors Company Evaluation Report 2025
• Neutral Sentiment: MiniMed priced its IPO at $20.00 per share for 28,000,000 shares — a procedural step that establishes a public valuation for the diabetes unit but doesn’t by itself show how Medtronic will deploy proceeds or adjust ownership. MiniMed announces pricing of initial public offering
• Negative Sentiment: MiniMed’s US IPO raised roughly $560 million — the market is interpreting the spin‑out as a catalyst for MDT selling pressure because it shifts future diabetes growth and cash flows away from the parent and may prompt portfolio rebalancing by investors. Medtronic’s diabetes unit MiniMed raises $560 million in US IPO

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).